Skip to main content
PepStack
Hormone · Profile

ACTH

Adrenocorticotropic Hormone · Corticotropin · Acthar

Pituitary & Trophic HormonesApproved
MW
4541g/mol
Formula
C207H308N56O58S

Adrenocorticotropic hormone (ACTH), a peptide hormone produced by the anterior pituitary gland, plays a crucial role in stimulating cortisol secretion from the adrenal glands. Researchers primarily study ACTH to understand its involvement in various endocrine disorders, particularly Cushing's disease, which is characterized by excessive ACTH production due to pituitary adenomas. Key findings indicate that elevated ACTH levels lead to increased cortisol, resulting in significant health issues such as hypertension, obesity, and metabolic syndrome. Furthermore, studies suggest that effective management of conditions related to ACTH dysregulation, including surgical resection of adenomas, can lead to biochemical remission and improved patient outcomes. Current research continues to explore the complexities of ACTH regulation and its implications for treatment strategies in related disorders.

Overview

Übersicht

Adrenocorticotropic hormone (ACTH), also known as corticotropin or Acthar, is an endogenous peptide hormone produced by the anterior pituitary gland. It belongs to the class of pituitary and trophic hormones. ACTH is synthesized as part of a larger precursor molecule, proopiomelanocortin (POMC), and is cleaved to produce the active hormone. It plays a crucial role in the endocrine system by regulating the secretion of glucocorticoids from the adrenal cortex. Researchers have observed that ACTH is primarily involved in the stress response, influencing the production of cortisol, a key stress hormone. It is also implicated in various pathological conditions such as Cushing's disease, where excess ACTH leads to elevated cortisol levels, resulting in metabolic and cardiovascular complications. ACTH acts on the melanocortin 2 receptor (MC2R) on the adrenal cortex, triggering a cascade that leads to the synthesis and release of cortisol. This hormone is involved in numerous physiological processes, including metabolism regulation, immune response modulation, and maintenance of homeostasis. Pharmacokinetic properties of ACTH include a pulsatile secretion pattern, influenced by the circadian rhythm and stress factors. The half-life of endogenous ACTH is relatively short, necessitating its continuous production for sustained action. Clinically, ACTH is used in diagnostic testing for adrenal insufficiency and as a therapeutic agent in certain inflammatory and autoimmune conditions. It is regulated as a prescription medication in many countries, reflecting its significant physiological impact and potential for misuse.

Chemical profile

Chemische Struktur

Chemical structure of ACTH
FormelC207H308N56O58S
Molekulargewicht4541g/mol
CAS-Nummer9002-60-2
PubChem CID16132265
Mechanism

Wirkmechanismus

ACTH acts primarily on the melanocortin 2 receptor (MC2R) located on the adrenal cortex, initiating a signaling cascade that results in the production and release of cortisol. This process involves the activation of adenylate cyclase, increasing cyclic AMP (cAMP) levels and stimulating steroidogenesis.

Mechanism

Signalweg

Adrenocorticotropic hormone (ACTH) primarily exerts its effects through the activation of melanocortin 2 receptors (MC2R) on adrenal cortical cells, initiating the cAMP/PKA signaling pathway. This activation stimulates the synthesis and secretion of glucocorticoids, particularly cortisol, from the adrenal cortex, thereby influencing various biological processes such as metabolism, immune response, and stress adaptation. The precise regulatory mechanisms of ACTH action, particularly in pathological states like Cushing's disease, remain an area of ongoing research.

Half-Life & Pharmacokinetics

ENEndogenous

Pulsatile, varies by time of day

IVIntravenous

Circulating half-life ~10 minutes

Endogenous ACTH has a short half-life, necessitating continuous secretion for sustained physiological effects.

Storage

Temperature

Refrigerate at 2-8C

Light

Protect from light

Form

Aqueous solution: use within specified period after opening

Notes

Ensure proper storage conditions to maintain stability and efficacy.

Solubility

Löslichkeit

ACTH is soluble in water, facilitating its formulation as an aqueous solution for clinical use.

Legal Status

🇩🇪DE

Verschreibungspflichtig (prescription only), not listed under BtMG.

🇺🇸US

FDA approved for diagnostic and therapeutic use; prescription required.

🇦🇺AU

TGA Schedule 4 (prescription only medicine).

🇬🇧UK

Prescription only medicine (POM) under MHRA regulations.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the long-term outcomes and quality of life in patients with Cushing's syndrome post-treatment, particularly in relation to the management of residual ACTH levels and their impact on morbidity and mortality. Further research is needed to explore the efficacy of CRF1 receptor antagonists like crinecerfont in diverse populations, including pediatric patients and those with varying degrees of disease severity. Additionally, larger randomized controlled trials are required to clarify the biological significance of different forms of ACTH, such as big ACTH, and their roles in various pathologies, including lung carcinoma and other malignancies.

75 Research Publications

2,626

Total Citations

16

Human/RCT

3.6

Avg. Influence

2025

Latest

Sort
Filter
#01

Neuroendocrine aspects of hypercortisolism in major depression.

ReviewInfluence17.0
455
Researchers observed that major depression is associated with altered HPA axis physiology, including hypersecretion of ACTH and cortisol during acute episodes.
#02

Regulation of the hypothalamic-pituitary-adrenal axis.

ReviewInfluence16.0
367
The study demonstrated that the hypothalamic-pituitary-adrenal axis, regulated by CRH and AVP, is crucial for cortisol synthesis and release in response to stress.
#03

Inhibition of adrenocorticotropic hormone secretion in the rat by immunoneutralization of corticotropin-releasing factor.

AnimalInfluence4.0
269
Researchers observed that immunoneutralization of corticotropin-releasing factor significantly reduced ACTH secretion in rats, indicating its physiological role in regulating ACTH release.
#04

Cushing's disease: pathobiology, diagnosis, and management.

Lonser Russell R, et al. · Journal of neurosurgery · 2017

ReviewInfluence8.0
157
Researchers observed that successful resection of ACTH-secreting pituitary adenomas in Cushing's disease leads to immediate biochemical remission and preservation of pituitary function.

Key findings

  1. 01Cushing's disease results from excess adrenocorticotropic hormone (ACTH) secretion.
  2. 02High cortisol levels are linked to severe health problems, including hypertension and obesity.
  3. 03Surgical removal of the tumor is the most effective treatment and can restore normal hormone levels.
#05

The renaissance of corticotropin therapy in proteinuric nephropathies.

ReviewInfluence6.0
101
The review highlighted that adrenocorticotropic hormone has antiproteinuric and renoprotective properties in nephrotic syndrome, suggesting its potential effectiveness in patients resistant to steroids and other immunosuppressants.
#06

Intrahypothalamic infusion of interleukin-1 beta increases the release of corticotropin-releasing hormone (CRH 41) and adrenocorticotropic hormone (ACTH) in free-moving rats bearing a push-pull cannula in the median eminence.

AnimalInfluence2.0
98
The study demonstrated that interleukin-1 beta infusion significantly increased the release of corticotropin-releasing hormone and ACTH in free-moving rats, indicating an interaction between the neuroendocrine and immune systems.
#07

Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans.

HumanInfluence2.0
91
Researchers observed that maternal plasma corticotropin-releasing hormone levels correlate with ACTH and cortisol during pregnancy, indicating its role as a stimulator of the maternal pituitary-adrenal axis.
#08

Hypothalamic Regulation of Corticotropin-Releasing Factor under Stress and Stress Resilience.

ReviewInfluence5.0
86
The review detailed that corticotropin-releasing factor in the hypothalamus regulates the stress response by stimulating adrenocorticotropic hormone release, with various factors contributing to stress resilience.
#09

Effect of urocortin on ACTH secretion from rat anterior pituitary in vitro and in vivo: comparison with corticotropin-releasing hormone.

AnimalInfluence4.0
85
The study demonstrated that urocortin is more potent than corticotropin-releasing hormone in stimulating ACTH secretion in rat anterior pituitary cells both in vivo and in vitro.
#10

Localization, expression and control of adrenocorticotropic hormone in the nucleus preopticus and pituitary gland of common carp (Cyprinus carpio L.).

AnimalInfluence1.0
56
Researchers observed that ACTH is produced in the pituitary gland of common carp and is regulated by factors from the nucleus preopticus, with dopamine exerting predominant inhibitory control over its release.

Clinical Trials (32)

Preclinical
Phase I
Phase II
Phase III
Approved

32

Total Trials

1,086

Total Enrolled

Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis

NCT00552487COMPLETED
Sponsor

University of Wuerzburg

Enrollment

62

Started

2005

Primary outcome

serum cortisol-peak 30 min after ACTH-stimulation

Hashimoto DiseaseAdrenal Insufficiency

ACTH vs Betamethasone in Hospitalized Patients With Acute Gout

Sponsor

University of Patras

Enrollment

60

Started

2018

Primary outcome

Pain VAS

Gout Attack

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Sponsor

Greater Boston Medical Associates

Enrollment

40

Started

2017

Primary outcome

level of proteinuria

Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function

Value of 25 mcg Cortrosyn Stimulation Test

NCT01428336COMPLETED
Sponsor

The Cleveland Clinic

Enrollment

22

Started

2011

Primary outcome

Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs

Adrenal Insufficiency

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

Sponsor

Ronald J. Rapoport, MD

Enrollment

10

Started

2014

Primary outcome

Percentage of patients with reduction of >1.2 points in DAS-28 score

Rheumatoid Arthritis

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177COMPLETED
Sponsor

The Cleveland Clinic

Enrollment

9

Started

2016

Primary outcome

Percentage of Patients With Clinically Significant Improvement in Visual Acuity

Ocular SarcoidosisPanuveitisAnterior Uveitis

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

NCT03042637SUSPENDED
Sponsor

Southeast Renal Research Institute

Started

2012

Primary outcome

Reduction of proteinuria in idiopathic membranous glomerulonephritis (MGN) and other forms of glomerulopathy including focal segmental glomerulosclerosis (FSGS) and advanced diabetic nephropathy

Nephrotic Syndrome

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

NCT02919761Phase 4COMPLETED
Sponsor

Mallinckrodt

Enrollment

259

Started

2016

Primary outcome

Part 1: Number of Participants With Low Disease Activity (LDA) by Visit

Arthritis, Rheumatoid

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554Phase 4COMPLETED
Sponsor

Mallinckrodt

Enrollment

60

Started

2011

Primary outcome

Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks

ProteinuriaIdiopathic Membranous Nephropathy

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

NCT01838174Phase 4TERMINATED
Sponsor

University of Colorado, Denver

Enrollment

37

Started

2013

Primary outcome

Retinal Nerve Fiber Layer (RNFL) thickness

Multiple Sclerosis

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760Phase 4TERMINATED
Sponsor

Mallinckrodt ARD LLC

Enrollment

35

Started

2017

Primary outcome

Score on the Expanded Disability Status Scale (EDSS) at Baseline and Day 42

Multiple Sclerosis, Relapsing-Remitting

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573Phase 4UNKNOWN
Sponsor

Iraj Sabahi Research Inc.

Enrollment

30

Started

2017

Primary outcome

ACR 20 response ACR 20 response

Rheumatoid Arthritis

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269Phase 4RECRUITING
Sponsor

Toyos Clinic

Enrollment

20

Started

2025

Primary outcome

Visual Analog scale for injection comfort

Autoimmune DiseasesDry EyeNeurotrophic Keratitis

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

NCT02446886Phase 4TERMINATED
Sponsor

Weill Medical College of Cornell University

Enrollment

15

Started

2016

Primary outcome

Change in Myelin Water Fraction (MWF) Within New Enhancing Lesions Over the Course of 12 Months

Multiple Sclerosis

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092Phase 4RECRUITING
Sponsor

University of California, San Francisco

Enrollment

14

Started

2022

Primary outcome

Decrease in blood CXCL9 levels by 50%

Sarcoidosis

ACTHar in the Treatment of Lupus Nephritis

NCT02226341Phase 4TERMINATED
Sponsor

Columbia University

Enrollment

8

Started

2014

Primary outcome

Number of Patients With a Complete Response (CR)

Lupus Nephritis

Evaluation of Neuroinflammation in Children With Infantile Spasms

NCT02092883Phase 4COMPLETED
Sponsor

Wayne State University

Enrollment

8

Started

2013

Primary outcome

Neuroinflammation in cortical and/or subcortical structures

Infantile Spasms

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697Phase 4COMPLETED
Sponsor

Tampa Bay Uveitis Center, LLC

Enrollment

6

Started

2016

Primary outcome

Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography

UveitisAnterior UveitisIntermediate UveitisPosterior UveitisScleritisClinically Significant Macular Edema

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

NCT03021317Phase 4TERMINATED
Sponsor

University of Chicago

Enrollment

5

Started

2016

Primary outcome

Change in T1 Lesion Relaxation Time

Multiple Sclerosis

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

NCT03656692Phase 4TERMINATED
Sponsor

Mallinckrodt

Enrollment

5

Started

2018

Primary outcome

Score on the Nussenblatt Grading Scale

Uveitis, PosteriorUveitis, IntermediatePanuveitis

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

NCT02769702Phase 4TERMINATED
Sponsor

Washington University School of Medicine

Enrollment

2

Started

2016

Primary outcome

Change From Baseline in Eye With Uveitis of Anterior Chamber Cellularity Graded From 0-4 on a Likert Scale Determined by Slit Lamp Examination

Uveitis

Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation

NCT06201897Phase 2/3RECRUITING
Sponsor

All India Institute of Medical Sciences

Enrollment

40

Started

2024

Primary outcome

Change in Cortical Excitability

West Syndrome

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895Phase 2/3TERMINATED
Sponsor

Neurologique Foundation, Inc.

Enrollment

30

Started

2009

Primary outcome

Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).

Multiple Sclerosis

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803Phase 2/3UNKNOWN
Sponsor

Albany Medical College

Enrollment

10

Started

2015

Primary outcome

Reduction of 24 hour urine calcium

SarcoidosisHypercalcemia Due to Sarcoidosis

ACTH in Progressive Forms of MS

NCT01950234Phase 2TERMINATED
Sponsor

University of Minnesota

Enrollment

59

Started

2014

Primary outcome

Proportion of Patients Exhibiting a 20% Worsening in T25FW at 36 Months

Secondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

NCT01984268Phase 2TERMINATED
Sponsor

Dartmouth-Hitchcock Medical Center

Enrollment

15

Started

2014

Primary outcome

Improvement in Disease Activity as Measured by ACR20 and ACR50.

Rheumatoid Arthritis

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372Phase 2COMPLETED
Sponsor

Rohit Aggarwal, MD

Enrollment

12

Started

2013

Primary outcome

Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).

DermatomyositisPolymyositis

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753Phase 1COMPLETED
Sponsor

Mayo Clinic

Enrollment

20

Started

2009

Primary outcome

Change in proteinuria

Idiopathic Membranous Nephropathy

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

NCT02486744Phase 1TERMINATED
Sponsor

Youngstown State University

Enrollment

9

Started

2015

Primary outcome

Renal Function

End Stage Renal Disease

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603Early Phase 1RECRUITING
Sponsor

University of Virginia

Enrollment

144

Started

2019

Primary outcome

Change in calculated free testosterone concentrations

Polycystic Ovary Syndrome

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

NCT01459237Early Phase 1COMPLETED
Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Enrollment

30

Started

2011

Primary outcome

To determine effect of CRH stimulation on 18F-FDG uptake in high-resolution PET-imaging of ACTH-adenomas in CD.

Pituitary Neoplasm

Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study

NCT03709381Early Phase 1COMPLETED
Sponsor

Nationwide Children's Hospital

Enrollment

10

Started

2017

Primary outcome

Difference between VEGF levels at baseline and the peak VEGF level after low dose cosyntropin administration in healthy children and adolescents

Adrenal InsufficiencyOsteopenia, OsteoporosisSteroid Suppression of ACTH Secretion

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer